VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
HALO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
HALOHalozyme Therapeutics, Inc.
$100.27$11.9B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. HALO
  4. Financial Ratios

Halozyme Therapeutics, Inc. (HALO) Financial Ratios

Latest Ratios: P/E Ratio 25.3x · EV/EBITDA 12.2x · ROE 153.6%. (2001–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

HALO Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$11.9B$8.3B$6.2B$5.0B$8.0B$5.9B$6.0B$2.6B$2.1B$2.8B$1.3B
Enterprise Value$13.9B$10.3B$7.6B$6.3B$9.3B$6.7B$6.3B$2.8B$2.2B$2.9B$1.4B
P/E Ratio →25.3326.2913.9417.6039.5114.6846.93——45.02—
P/S Ratio6.605.976.095.9812.1213.3122.5813.0613.838.908.62
P/B Ratio254.51170.8317.0159.1847.1229.9740.0027.898.4413.52—
P/FCF13.4312.9413.2113.2934.0019.81114.11——21.23—
P/OCF18.2512.8012.9212.7633.3219.71108.95——21.02—

P/E links to full P/E history page with 30-year chart

HALO EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—7.417.467.6514.0515.0223.5114.5014.289.019.64
EV / EBITDA12.2311.6211.9815.0129.2323.8842.64——34.28—
EV / EBIT17.3221.3413.1717.2734.8826.0142.03——35.20—
EV / FCF—16.0516.1816.9939.4122.35118.82——21.49—

HALO Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin83.6%83.6%84.3%76.8%78.9%81.6%83.8%76.8%93.3%90.2%77.4%
Operating Margin57.5%57.5%54.3%40.7%40.5%62.2%53.9%-34.5%-45.7%25.6%-56.7%
Net Profit Margin22.7%22.7%43.7%34.0%30.6%90.8%48.2%-36.9%-52.9%19.9%-70.2%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE153.6%153.6%198.4%222.1%110.2%231.4%106.3%-42.4%-35.1%71.6%-1959.0%
ROA13.8%13.8%23.4%15.8%13.7%47.8%22.5%-14.4%-16.7%16.1%-46.5%
ROIC31.6%31.6%25.7%17.4%16.7%30.5%27.9%-14.7%-18.6%33.8%-74.8%
ROCE37.6%37.6%31.1%20.3%19.8%48.2%45.2%-17.5%-20.4%27.2%-51.0%

HALO Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity43.8943.894.1417.898.874.452.634.390.510.97—
Debt / EBITDA2.412.412.383.554.753.142.69——2.43—
Net Debt / Equity—41.153.8216.487.493.851.653.080.280.16—
Net Debt / EBITDA2.262.262.203.274.012.721.69——0.40—
Debt / FCF—3.122.973.705.412.544.71——0.25—
Interest Coverage26.7626.7631.7919.5715.6934.027.35-5.21-3.843.68-4.10

HALO Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio4.664.667.806.645.657.911.326.352.863.894.70
Quick Ratio3.663.666.785.504.887.451.176.002.713.854.43
Cash Ratio0.810.814.292.992.776.320.874.922.373.573.76
Asset Turnover—0.550.490.480.360.400.460.350.340.610.56
Inventory Turnover1.301.301.121.511.391.510.711.550.456.052.27
Days Sales Outstanding—115.33110.89103.09127.7774.90133.30110.7072.1225.5239.02

HALO Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield3.9%3.8%7.2%5.7%2.5%6.8%2.1%——2.2%—
FCF Yield7.4%7.7%7.6%7.5%2.9%5.0%0.9%——4.7%—
Buyback Yield2.9%4.1%4.0%8.1%2.5%5.9%2.5%7.8%0.0%0.0%0.0%
Total Shareholder Yield2.9%4.1%4.0%8.1%2.5%5.9%2.5%7.8%0.0%0.0%0.0%
Shares Outstanding—$124M$129M$134M$141M$147M$141M$144M$144M$139M$128M

Key Metrics

Growth RegimeExpanding
ProfitabilityStrong
Balance SheetMixed
Cash FlowRobust
Top Statement Risk

Negative equity and rising leverage

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Trailing Multiples Overstate Forward Earnings Discount

Based on reported figures, HALO trades at 25.7x trailing P/E but only 11.8x forward P/E, a gap that suggests consensus expects earnings to roughly double as revenue momentum continues.

The compression from trailing to forward P/E implies the market is pricing in a meaningful earnings step-up rather than paying for current reported profit, which was distorted by the 2025Q4 net loss. The PEG of 1.12 sits near the fair-value threshold, suggesting the growth premium is roughly priced in, though investors should monitor whether forward estimates hold given quarterly volatility. Against peers, HALO's EV/EBITDA of 12.4x is reasonable relative to ALNY at 20.3x and EXEL at 16.9x, but the 258x price-to-book reflects a shrinking equity base and offers little useful valuation signal.

Operating Margins Sustained Above Fifty Percent

As reported in financial statements, HALO's operating margin reached 59.8% in 2026Q3 with gross margin at 83.3%, levels that sit well above most of the peer set and indicate a highly scalable royalty-style revenue model.

Operating margin has held in a 49% to 62% band across the ten quarters, implying that incremental revenue is converting to operating income at a high rate with SG&A largely fixed. Net margin of 50.1% in the latest quarter is consistent with this, although the 2025Q4 negative net margin of -31.3% reflects non-operating or tax items rather than deteriorating operations, making operating margin a more reliable gauge of earning power. The durability of these margins warrants further investigation given the concentration of the revenue base.

Returns Recovering From Mid-Cycle Trough

According to recent reported figures, HALO's ROIC rose from 5.6% in 2024Q2 to 10.3% in 2026Q3, a recovery that appears driven mainly by margin expansion rather than improved capital efficiency.

ROE readings are heavily distorted by a shrinking equity base, with the 126.6% figure in 2026Q2 and the negative equity implied in 2026Q3 making ROE not meaningful as a compounding measure. ROIC is the more reliable indicator here, and its improvement from the 2024 trough suggests returns are recovering, though at roughly 10% they remain modest relative to ALNY's 93.2% and EXEL's 32.1%. Investors should monitor whether ROIC can be sustained as buybacks reduce equity and alter the invested capital base.

Debt Expansion Outpaces Equity Cushion

Based on reported figures, HALO's debt-to-EBITDA ratio stands at 9.9x in 2026Q3 against interest coverage of 49.1x, a combination that suggests debt service remains comfortable on current earnings even as the balance sheet grows more leveraged.

Total debt rising from roughly $1.5B to $3.3B while equity turned negative points to a capital structure increasingly funded by liabilities, which may indicate reduced flexibility should earnings weaken. Interest coverage above 30x in most quarters implies current operating income covers financing costs comfortably, yet the D/EBITDA trajectory from 3.1x in 2025Q1 to 9.9x suggests leverage has risen faster than cash generation. Refinancing terms and covenant headroom are not disclosed in the supplied data, so these conclusions should be treated as analytical inference warranting further review.

Trailing Margins Misread as Earnings Durability

The ratio most commonly misapplied to HALO is operating margin treated as a durable earnings measure, since the 59.8% figure may reflect concentrated royalty streams rather than a broadly diversified and repeatable profit base.

Investors often read sustained margins above 50% as evidence of a defensible franchise, but this can obscure dependence on a narrow set of licensed products and milestone timing that drives quarterly volatility. A better complement is free cash flow margin on a trailing twelve-month basis combined with revenue concentration by product, which would show whether the cash output is recurring. Given that net margin swung from 47.8% to -31.3% within two quarters, operating margin alone appears insufficient as a guide to underlying earning power.

Download Financial Ratios Data

Includes 30+ ratios · 25 years · Updated daily

Consensus & Technical Research Suite
Open HALO Terminal

HALO Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

HALO — Frequently Asked Questions

Quick answers to the most common questions about buying HALO stock.

What is Halozyme Therapeutics, Inc.'s P/E ratio?

Halozyme Therapeutics, Inc.'s current P/E ratio is 25.3x. The historical average is 29.1x. This places it at the 43th percentile of its historical range.

What is Halozyme Therapeutics, Inc.'s EV/EBITDA?

Halozyme Therapeutics, Inc.'s current EV/EBITDA is 12.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 24.1x.

What is Halozyme Therapeutics, Inc.'s ROE?

Halozyme Therapeutics, Inc.'s return on equity (ROE) is 153.6%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -32.3%.

Is HALO stock overvalued?

Based on historical data, Halozyme Therapeutics, Inc. is trading at a P/E of 25.3x. This is at the 43th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Halozyme Therapeutics, Inc.'s profit margins?

Halozyme Therapeutics, Inc. has 83.6% gross margin and 57.5% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.

How much debt does Halozyme Therapeutics, Inc. have?

Halozyme Therapeutics, Inc.'s Debt/EBITDA ratio is 2.4x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.